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Background: Venous thromboembolism (VTE) is a burden on healthcare systems. Standard treatment involves
parenteral anticoagulation overlapping with a vitamin K antagonist, an approach that is effective but associated
with limitations including the need for frequent coagulation monitoring. The direct oral anticoagulant rivaroxaban
is similarly effective to standard therapy as a single-drug treatment for VTE and does not require routine coagulation
monitoring. The objective of this economic evaluation was to estimate the cost-effectiveness of rivaroxaban
compared with standard VTE treatment from a UK perspective.
Methods: A Markov model was constructed using data and probabilities derived from the EINSTEIN DVT and
EINSTEIN PE studies of rivaroxaban and other published sources. Health outcomes included VTE rates, bleeding
events avoided, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).
Results: There was greater discounted quality-adjusted life expectancy with rivaroxaban than with standard therapy,
irrespective of indication and treatment duration. Rivaroxaban was associated with per-patient cost savings for each
treatment duration modelled (3, 6 and 12 months), and these were greatest with shorter durations. Rivaroxaban
was found to be dominant (cheaper and more effective) and, therefore, cost-effective, in both patients with deep
vein thrombosis and pulmonary embolism in all three treatment duration groups, and was also cost-effective in
patients requiring lifelong anticoagulation (ICERs: £8677 per QALY and £7072 per QALY in patients with index deep
vein thrombosis and pulmonary embolism, respectively). The cost-effectiveness of rivaroxaban was largely insensitive to
variations in one-way sensitivity analysis. Probabilistic sensitivity analysis demonstrated that at a threshold of
£20,000 per QALY, rivaroxaban had a consistent probability of being cost-effective, compared with LMWH/VKA
treatment, of around 80% regardless of index VTE or duration of anticoagulation therapy (3, 6, 12 months or lifelong).
Conclusions: This analysis suggests that rivaroxaban represents a cost-effective choice for acute treatment of deep
vein thrombosis and pulmonary embolism and secondary prevention of VTE in the UK, compared with LMWH/VKA
treatment, regardless of the required treatment duration.
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Venous thromboembolism (VTE) is both an acute, po-
tentially life-threatening and chronic condition that con-
tinues to present a burden to healthcare systems [1-3].
The annual incidence of VTE, which includes deep vein
thrombosis (DVT) and pulmonary embolism (PE), has
been estimated at 1–2 cases per 1000 persons per year
in western populations [4-6] as well as in the UK [7].
Long-term sequelae of VTE include recurrent thrombo-
embolism, post-thrombotic syndrome (PTS) and chronic
thromboembolic pulmonary hypertension (CTEPH) [8,9].
These serious complications further add to the burden of
managing VTE [10].
In the UK, treatment of acute DVT and PE and pre-
vention of recurrent VTE primarily involve the use of
anticoagulant therapy. Current standard of care consists
of initial treatment with a parenteral anticoagulant, often
low molecular weight heparin (LMWH; administered by
subcutaneous injection) overlapping with a vitamin K
antagonist (VKA), typically warfarin [11-13]. However,
VKAs have various limitations, including a narrow thera-
peutic range, a requirement for dose adjustment, a re-
sponse that is easily influenced by diet and concomitant
medication, and a requirement for frequent international
normalized ratio (INR) monitoring [14]. The typical on-
going frequency of monitoring in the UK is every 3–4
weeks, but it can be even more frequent, particularly dur-
ing initiation of treatment [15-18]. The objective of moni-
toring is to maintain the INR level within the therapeutic
range to prevent the recurrence of VTE while minimizing
the increased risk of bleeding. The resulting need for rou-
tine collection of blood samples and subsequent labora-
tory analysis can make the use of VKAs inconvenient for
patients and imposes a cost and management burden on
healthcare systems [19-21]. LMWHs are also associated
with safety issues, particularly when used without careful
individualized dosing [22], and furthermore, patients with
poor dexterity may experience difficulties with subcutane-
ous self-administration.
There is no clear consensus on the optimal duration
of anticoagulant treatment in the UK; however, treat-
ment is generally recommended for at least 3 months
after the venous thromboembolic event [15,23], and then
possibly extended with regular reassessments [12]. In a
retrospective observational study, variations in the dur-
ation of anticoagulation treatment were observed in UK
anticoagulation treatment practice, confirming the rele-
vance of the EINSTEIN trial approach of comparing
across patient populations requiring different durations
of treatment [24].
The EINSTEIN DVT and EINSTEIN PE studies were
designed to investigate the efficacy and safety of rivarox-
aban compared with standard therapy in the treatment
of patients with confirmed acute, symptomatic DVT orPE, respectively [25,26]. In both trials, patients were ran-
domized in an open-label, event-driven, non-inferiority
study design that compared 3 weeks of rivaroxaban 15 mg
twice daily followed by 20 mg once daily for an additional
3, 6 or 12 months, with standard dual-drug therapy
(LMWH [enoxaparin] followed by a VKA) [25,26]. The
duration of therapy was selected by the treating clin-
ician to reflect local preferences, the underlying risks
arising from the nature of the index VTE, characteristics
of the patient, and ongoing risk of recurrent VTE or
bleeding [25,26].
Results of both studies showed non-inferiority of rivar-
oxaban for the primary efficacy endpoint (the composite
of recurrent DVT and fatal and non-fatal PE) compared
with the current standard therapy [25,26]. In a pooled
analysis of the two studies, rivaroxaban showed a similar
incidence to standard therapy for the principal safety out-
come of major and non-major clinically relevant bleeding;
there was also a significant reduction in the incidence of
major bleeding with rivaroxaban (hazard ratio 0.54; 95%
confidence interval [CI] 0.37–0.79; p = 0.002) [27].
Although the drug acquisition costs of rivaroxaban
may be higher than those associated with LMWH/VKA
therapy, it is possible that rivaroxaban therapy may be more
cost-effective, owing to the complexities of VKA therapy,
particularly the frequent INR monitoring. Rivaroxaban has
been shown to be cost-effective for the prevention of VTE
compared with enoxaparin in a UK model [28]. However,
published data surrounding the potential cost-effectiveness
of rivaroxaban in VTE treatment are scarce. The objective
of this economic evaluation was to estimate, from the per-
spective of the UK National Health Service (NHS), the
cost-effectiveness of rivaroxaban compared with standard
care in the treatment of acute DVT or PE based on the
findings of the EINSTEIN DVT and EINSTEIN PE stud-
ies. The model presented here provided the basis for the
health economic evidence submissions made to the UK
National Institute for Health and Care Excellence (NICE)




A Markov model design was selected after a review of
the existing cost-effectiveness literature and based on
consultation with UK clinical and health economic ex-
perts [31-34]. Patients entered the model after a diagno-
sis of VTE; these patients were categorized according to
whether they had experienced an index DVT or PE. Pa-
tient progression between model health states was ac-
cording to 3-month cycles and transition probabilities
derived from the EINSTEIN clinical trials or published
studies. The model time horizon was 40 years, approxi-
mating to a lifetime for this patient group. The health
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cations of initial VTE management as well as potential
complications (Table 1 and Figure 1).
The analysis was undertaken from a UK payer perspec-
tive (NHS and personal social services) in accordance with
the NICE Reference Case [35]. An annual discount rate
equal to 3.5% was adopted for costs and outcomes [35].
Health outcomes modelled included numbers and rates of
venous thromboembolic events, bleeding events avoided,
quality-adjusted life-years (QALYs) and economic out-
comes such as costs and incremental cost-effectiveness
ratios (ICERs).
Patient population and treatment
Patients entering the model mirrored the inclusion cri-
teria for the EINSTEIN DVT and EINSTEIN PE studiesTable 1 Descriptions of the health states in the DVT and PE m
State name Description
On Tx Patients who have just experienced an acute VT
3, 6 or 12 months or lifetime treatment with riva
rVTE – DVT Patients who have just experienced a recurrent
receive 6 months of dual LMWH/VKA. The durat
events were not associated with excess mortalit
rVTE – PE Patients who have just experienced a recurrent
to capture PTS risk. Assigned therapy was discon
VKA. The duration of utility impact was assumed
excess mortality
Major bleed – IC Patients on assigned therapy who have just exp
the cycle in which the IC bleeding event took p
Major bleed – EC Patients on assigned therapy who have just exp
Therapy was temporarily withheld for 1 month d
utility impact was assumed to be 1 month in th
NMCR bleed Patients on assigned therapy who have just exp
meet the criteria for major bleeding but was ass
physician, interruption or discontinuation of a st
was temporarily withheld for 1 month during th
would be spontaneous bleeding from gums wh
not to impact on utility
Post-IC bleed Patients who previously experienced an IC bleed
are associated with major risks of residual disabi
health-related quality of life and costs associated
Off Tx-post index PE* Patients currently off treatment after index PE. T
Off Tx-post DVT Patients who have experienced an incident DVT
treatment. These patients are at risk of PTS
On Tx-post DVT This state is only applicable to analyses of lifelon
within the time frame of the model and who ar
PE post DVT* Patients with recurrent PE and a history of DVT w
continue exposure to a risk of PTS conferred by
CTEPH Patients diagnosed with CTEPH who are expose
excess mortality
Long-term CTEPH State to which patients with CTEPH transition in
Death Terminal state. Patients could die because of eit
other causes
*PE model-specific health states.
CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombo
NMCR, non-major clinically relevant; PE, pulmonary embolism; PTS, post-thrombotic
vitamin K antagonist; VTE, venous thromboembolism.and had a mean age of 56 and 58 years at baseline, re-
spectively [25,26]. The duration of rivaroxaban or stand-
ard therapy (LMWH/VKA) – 3, 6 or 12 months – was
determined according to each patient’s risk profile.
Rivaroxaban was administered according to its subse-
quently licenced schedule for DVT and PE treatment:
15 mg twice daily for 21 days followed by 20 mg once
daily for the remaining duration of anticoagulation treat-
ment [36]. For dual-drug therapy with LMWH/VKA,
LMWH was continued until therapeutic anticoagulation
with a VKA had been established [37]. Based on the study
design of EINSTEIN DVT and EINSTEIN PE [25,26], and
the pattern of LMWH use in the UK, enoxaparin was se-
lected as the LMWH for the model. The daily dose of
enoxaparin was 1.5 mg/kg, in alignment with the regimen
licensed for the UK [12]. The LMWH/VKA comparatorodels
E, and are receiving one of the acute treatments being evaluated (either
roxaban or dual LMWH/VKA therapy)
DVT. Assigned therapy was discontinued and all patients assumed to
ion of utility impact was assumed to be 1 month in the base case. DVT
y
PE (± DVT). Patients with coincident DVT transit to a post-DVT state
tinued and all patients assumed to receive 6 months of dual LMWH/
to be 1 month in the base case. PE events were associated with
erienced an IC bleeding event. Therapy was temporarily withheld during
lace. IC bleeding events were associated with excess mortality
erienced a major EC bleeding event (e.g. gastrointestinal bleeding).
uring the cycle in which the bleeding event took place. The duration of
e base case
erienced a NMCR bleeding event. Defined as overt bleeding that did not
ociated with medical intervention, unscheduled contact with a
udy drug, or discomfort or impairment of activities of daily life. Therapy
e cycle in which the bleeding event took place. An example of this
ich requires acute medical intervention. NMCR bleeding was assumed
ing event. Any assigned therapy is assumed to stop. IC bleeding events
lity stemming from their impact on the central nervous system. The
with this are included
hese patients are not at ongoing risk of PTS
within the time frame of the model and who are currently off
g treatment duration. Patients who have experienced an incident DVT
e currently on treatment. These patients are at risk of PTS
ithin the model. Survivors return to relevant post-DVT states so as to
their DVT history
d to management costs, health-related quality of life loss and
the long term
her events captured in the model, such as PE or IC bleed, or from
sis; EC, extracranial; IC, intracranial; LMWH, low molecular weight heparin;
syndrome; rVTE, recurrent venous thromboembolism; Tx, treatment; VKA,
Figure 1 State diagram for the economic model. The model states referred to here are described in Table 1. Note that states, On Tx-post DVT,
and, PE post DVT, were specific to analyses for patients post index PE and have been omitted from the diagram. PTS risk was restricted to states
with a DVT history in the PE analysis. CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; EC, extracranial; IC,
intracranial; NMCR, non-major clinically relevant; PE, pulmonary embolism; PTS, post-thrombotic syndrome; rVTE, recurrent venous thromboembolic
event; Tx, treatment.
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was in concordance with guidelines [15,23] and observed
practice in the UK [24]. A scenario evaluating patients
with persisting risk of VTE requiring lifelong anticoagula-
tion was included.
Model input data
Clinical parameters and variables
For patients receiving dual-drug therapy with LMWH/
VKA, the baseline incidences of recurrent VTE, major
bleeding and non-major clinically relevant bleeding were
derived from EINSTEIN DVT and EINSTEIN PE [25,26].
These were evaluated according to intended treatment
duration to account for differences in patient risk profiles
(Table 2). Transition probabilities during the on-treatment
period were also differentiated according to time since the
index event, to account for changes in VTE risk over time.
The effect of rivaroxaban was assumed to apply while a
patient was on treatment. Treatment effects were applied
as either hazard ratios or relative risks and taken from ei-
ther EINSTEIN DVT or EINSTEIN PE, depending on the
index event for the cohort. Consistent with the NICE Ref-
erence Case, treatment effects were applied regardless of
significance [35].
Composite outcomes were disambiguated according to
the observed split in each trial (Table 3). Additionally,
for the PE cohort, the model considered the proportion
of recurrent PE patients with concurrent DVT (3.4%), to
account for differences in long-term risk of PTS.
Longer-term implications of anticoagulant treatment
were estimated based on published data identified in asystematic literature review (Table 3) [25,26,38-43]. Based
on the index event, patients were exposed to either a
long-term risk of PTS (post DVT) or CTEPH (post PE).
The additional risk of either PTS or CTEPH was cap-
tured for recurrent VTE. The risk of recurrent VTE
while off treatment was based on long-term observa-
tional research [41].
The risk of mortality comprised two parts: the age-
associated risk for the patient population, sourced from
UK life tables from the Office of National Statistics
(www.ons.gov.uk), and the risk of mortality associated
with particular model events. Events associated with add-
itional mortality included: PE during both the acute treat-
ment and secondary prevention phase, PE after the
treatment phase, major intracranial bleeding, major ex-
tracranial bleeding, and CTEPH. These risks were in-
formed by systematic literature review (Table 3). With
the exception of the ongoing risk for mortality from
CTEPH, each mortality risk was applied once in the
model, at the time of the relevant event.
Utility values
Evidence of utility values associated with VTE, including
events such as DVT, PE, bleeding, CTEPH and PTS, in
patient populations with VTE, was sought through sys-
tematic literature review [44-47]. The review also set out
to identify evidence that might suggest moderation of
utilities according to the nature of treatment received.
The starting point in the modelling of utility in the phar-
macoeconomic evaluation was the population norm value
of 0.825 established in the landmark national EQ-5D
Table 2 Incidence of clinical events in EINSTEIN DVT [25]
and EINSTEIN PE [26]
Probability, mean (SE) EINSTEIN DVT EINSTEIN PE
Recurrent VTE (LMWH/VKA)
3-month population
0–3 months 0.015 (0.008) 0.016 (0.011)
6-month population
0–3 months 0.024 (0.005) 0.016 (0.003)
3–6 months 0.003 (0.002) 0.002 (0.001)
12-month population
0–3 months 0.035 (0.009) 0.015 (0.004)
3–6 months 0.008 (0.004) 0.003 (0.002)
6–12 months 0.003 (0.003) 0.001 (0.001)
Lifelong population [61]
>12 months 0.700 (0.107) 0.700 (0.107)
Major bleeding (LMWH/VKA)
3-month population
0–3 months 0.020 (0.010) 0.041 (0.018)
6-month population
0–3 months 0.009 (0.003) 0.010 (0.003)
3–6 months 0.004 (0.002) 0.008 (0.003)
12-month population
0–3 months 0.002 (0.002) 0.013 (0.004)
3–6 months – (0.002) 0.004 (0.002)
6–12 months – (0.002) 0.006 (0.003)
Lifelong population [61]
>12 months 1.600 (0.245) 1.600 (0.245)
NMCR bleeding (LMWH/VKA)
3-month population
0–3 months 0.060 (0.017) 0.066 (0.022)
6-month population
0–3 months 0.047 (0.006) 0.067 (0.007)
3–6 months 0.013 (0.004) 0.022 (0.004)
12-month population
0–3 months 0.049 (0.01) 0.062 (0.008)
3–6 months 0.024 (0.008) 0.029 (0.006)
6–12 months 0.038 (0.01) 0.030 (0.006)
Lifelong population
>12 months 0.014 (0.002) 0.022 (0.002)
LMWH, low molecular weight heparin; NMCR, non-major clinically relevant; SE
standard error; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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evaluation. The utility values adopted for the cost-
effectiveness analyses are summarized in Table 4.
The most appropriate evidence on the disutility for
DVT, PE, major extracranial bleeding (assumed to match
the disutility reported for gastrointestinal bleeding) andintracranial bleeding (assumed to match the disutility re-
port for haemorrhagic stroke) was an evaluation of pa-
tient preferences in VTE [46]. Treatment satisfaction
with rivaroxaban has been shown to be higher than with
LMWH/VKA in the EINSTEIN studies [49,50]. Therefore,
it was reasonable to assume that VKA treatment was asso-
ciated with a disutility. All other utility assumptions were
made independent of treatment arm.
Cost and resource input data
The model includes resource consumption related to the
index event with respect to drug acquisition components
and associated monitoring requirements (Table 5). Pa-
tients in the LMWH/VKA arm of the model initially
require acute treatment with LMWH, overlapping with
and followed by a VKA.
Because warfarin is the most commonly used VKA for
VTE treatment in the UK [12], and was also the
most frequently used VKA in the EINSTEIN DVT and
EINSTEIN PE studies [25,26], it was selected for the model.
To facilitate understanding of the contemporary provision
of anticoagulation care, a survey of models of care was
conducted (Bayer, data on file) [51]. Results suggested
that, instead of traditional secondary care (consultant-led
services), primary care is now the most common setting
for provision of these services. Therefore, based on the re-
sults of this survey, the primary care-setting cost was ap-
plied in 66.5% of cases and the secondary care-setting cost
in the remaining 33.5% of cases; transport services were
required by 8.6% of patients managed in secondary care.
It was assumed that patients receiving a VKA would re-
quire a mean of nine coagulation monitoring visits in
the first 3 months and five visits per quarter thereafter
(Table 6) [15,18,25,51].
In addition, both the EINSTEIN DVT and EINSTEIN
PE studies demonstrated that hospitalized patients treated
with rivaroxaban had significantly shorter durations of
admission than patients treated with LMWH/VKA [52].
Savings related to this for the index event were included
in the analyses. The economic model also accounted for
resource usage associated with bleeding (of various types/
severities), recurrent VTE, PTS and CTEPH (Table 6).
Unit costs
Unit costs used in the model were taken wherever possible
from the NHS National Schedule of Reference Costs, the
Personal Social Services Research Unit and the British Na-
tional Formulary [18,53,54]. All unit costs assumed in the
economic model are listed in Additional file 1, together
with the source and rationale for each value [18,53-58].
Analyses performed
The base case evaluated the costs and health outcomes of
rivaroxaban compared with dual LMWH/VKA therapy
Table 3 Overview of assumed clinical parameters for DVT and/or PE patients
Probability, mean (SE) DVT patients PE patients Source
Event/outcome
Incidence of recurrent VTE (HR) 0.68 (0.218) 1.123 (0.207) *
Incidence of major bleeding (HR) 0.646 (0.242) 0.493 (0.24) *
Incidence of NMCR bleeding (RR) 1.055 (0.123) 1.001 (0.088) *
Probability that a recurrent VTE is a DVT 0.483 (0.054) 0.372 (0.050) *
Probability that a major bleeding event is a (major) IC bleed 0.125 (0.058) 0.143 (0.076) *
Discontinuation
Patients with IC bleeding events 1.00 (0.0) 1.00 (0.0) *
Patients with major EC bleeding events 0.400 (0.089) 0.164 (0.045) *
Patients with NMCR bleeding events 0.110 (0.020) 0.054 (0.010) *
For any other reason (additional) 3–12 months 0.019 (0.001) 0.021 (0.001) *
For any other reason (additional) >12 months 0.036 (0.013) 0.036 (0.013) Boggon 2011 [62]
DVT and PE patients
Risks of subsequent morbidities
Recurrent VTE (per 3-month time step) 0.013 (0.074) Prandoni 2007 [41]
Progression to CTEPH after a PE 0.013 (0.002) Miniati 2006 [38]
Cumulative incidence of severe PTS (to 1 year) 0.027 (0.007) Prandoni 1997 [40]
Cumulative incidence of severe PTS (to 5 years) 0.081 (0.012) Prandoni 1997 [40]
Mortality associated with another model event
PE (during acute treatment phase) 0.250 (0.041) *
PE (after acute treatment phase) 0.331 (0.041) Prandoni 1997 [40]
Major IC bleeding 0.436 (0.036) Linkins 2010 [42]
Major EC bleeding 0.039 (0.007) *
CTEPH (per 3-month cycle) 0.025 (0.020) Condliffe 2008 [43]
*Data are from EINSTEIN DVT or EINSTEIN PE unless otherwise stated [25,26].
CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; EC, extracranial; HR, hazard ratio; IC, intracranial; NMCR, non-major clinically
relevant; PE, pulmonary embolism; PTS, post-thrombotic syndrome; RR, relative risk; SE, standard error; VTE, venous thromboembolism.
Table 4 Utility values assumed in the cost-effectiveness evaluation
Model state Mean Sensitivity analyses Source
Lower Upper
Population norm 0.825 0.819 0.831 Kind 1998 [48]
Post-IC bleeding 0.71 0.70 0.72 Rivero-Arias 2010 [44]
CTEPH 0.56 0.53 0.59 Meads 2008 [45]
Adjustments to utility norm due to modelled events
DVT 0.84 0.64 0.98 Locadia 2004 [46]
PE 0.63 0.36 0.86 Locadia 2004 [46]
EC bleeding (gastrointestinal bleeding was the disease state valued) 0.65 0.49 0.86 Locadia 2004 [46]
IC bleeding (haemorrhagic stroke was the disease state valued) 0.33 0.14 0.53 Locadia 2004 [46]
PTS (serious PTS was the disease state valued) 0.93 0.91 1.00 Lenert 1997 [47]
Locadia et al. quoted a population norm (own health) as 0.95 (95% confidence interval [CI] 0.81–1.00) [46]. Utility values were adjusted according to this value
before adjusting for UK population norm.
Lower and upper values are estimates of 95% CIs from data presented (e.g. sample population size, n and standard deviation) in the source literature.
The 95% CIs for DVT, PE, and EC and IC bleeding adjustments to utility norms have been assumed to equal the interquartile range because of the absence of
further information and the size of the sample in Locadia et al. [46].
For the probabilistic sensitivity analyses, the parameters above were modelled as arising from independent beta distributions with alpha and beta parameters set
such that the mean is the point estimate and the lower and upper values represent the 95% CI.
CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; EC, extracranial; IC, intracranial; PE, pulmonary embolism; PTS,
post-thrombotic syndrome.
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Table 5 Base case results
EINSTEIN DVT EINSTEIN PE
Rivaroxaban Dual LMWH/
VKA therapy
Incremental Rivaroxaban Dual LMWH/
VKA therapy
Incremental
Patients appropriate for 3 months of anticoagulation
Drug acquisition cost (£) 220 98 122 217 99 118
Other costs (£) 1592 1964 −372 4295 4808 −513
Total costs (£) 1812 2063 −251 4511 4907 −396
QALYs 13.286 13.264 0.022 11.940 11.912 0.027
ICER (£) Rivaroxaban dominates Rivaroxaban dominates
Patients appropriate for 6 months of anticoagulation
Drug acquisition cost (£) 398 104 295 393 105 288
Other costs (£) 1561 2040 −479 4153 4654 −501
Total costs (£) 1959 2143 −184 4546 4759 −213
QALYs 13.294 13.268 0.026 11.992 11.979 0.013
ICER (£) Rivaroxaban dominates Rivaroxaban dominates
Patients appropriate for 12 months of anticoagulation
Drug acquisition cost (£) 731 114 617 728 115 613
Other costs (£) 1512 2186 −673 4154 4900 −746
Total costs (£) 2243 2299 −56 4881 5015 −133
QALYs 13.308 13.274 0.034 12.035 12.015 0.020
ICER (£) Rivaroxaban dominates Rivaroxaban dominates
Patients appropriate for lifelong anticoagulation
Drug acquisition cost (£) 6566 288 6278 6025 284 5740
Other costs (£) 2084 6835 −4751 4532 9209 −4677
Total costs (£) 8649 7122 1527 10,557 9493 1064
QALYs 13.507 13.331 0.176 12.526 12.375 0.150
ICER (£) 8677 7072
ICER, incremental cost-effectiveness ratio; LMWH, low molecular weight heparin; QALY, quality-adjusted life-year; VKA, vitamin K antagonist.
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3, 6 or 12 months, reflecting the design of EINSTEIN
DVT and EINSTEIN PE. In addition, a scenario analysis
was undertaken comparing rivaroxaban with LMWH/
VKA for patients requiring lifelong anticoagulation.
Sensitivity analyses
To identify key model drivers, all inputs were subject to
univariate sensitivity analyses. Clinical parameters were
varied between 95% CIs. Utility value assumptions were
varied between 95% CIs or, where these were not avail-
able, the interquartile range. Mean age at baseline was
varied between 45 and 75 years. Resource usage was var-
ied as described in Table 6 and unit cost values were var-
ied by interquartile ranges. The setting of INR monitoring
varied from a mixture of primary and secondary care, as
described previously, to either 100% primary or 100% sec-
ondary care.
Probabilistic sensitivity analyses were conducted to es-
timate the effect of overall uncertainty in the economicevaluation through repeated sampling of mean parameter
values from a series of assigned distribution types. The
analyses were used to generate cost-effectiveness planes
and cost-effectiveness acceptability curves across patients
requiring different treatment durations. The type of distri-
bution applied to a given parameter was dependent on the
nature of that parameter (Tables 1, 2, 3, 4, 5 and 6).
Results
Results are presented according to the index event and
appropriate duration of anticoagulation therapy (Table 5).
There was greater discounted quality-adjusted life expect-
ancy with rivaroxaban than with LMWH/VKA, irrespect-
ive of indication and treatment duration. Rivaroxaban was
associated with per-patient cost savings for each of the
trial-based treatment durations (3, 6 and 12 months). Sav-
ings were greatest with shorter treatment durations. As a
consequence, rivaroxaban was found to be dominant
(cheaper and more effective) and, therefore, cost-effective,
in both DVT and PE patients in all three treatment
Table 6 Summary of resource usage assumptions
Resource item Mean Sensitivity analyses Rationale
Lower Upper Distribution
Acute treatment
Number of days of acute treatment (i.e. LMWH) required
by a DVT patient
9.6 6 10 Dirichlet EINSTEIN DVT [25]
SIGN guidelines [15]
Number of days of acute treatment (i.e. LMWH) required
by a PE patient
9.7 7 13 Dirichlet Mean duration from EINSTEIN PE [26]
Proportion of patients who self-inject LMWH (%) 92 64.40 100 Beta The point estimate is taken from the
assumptions in NICE CG92 [56]. The
sensitivity range is an assumption
Proportion of remaining patients who require nurse
assistance at home (%)
80 60 100% Beta These values are assumptions based
on inputs determined for the NICE
CG92 model
INR monitoring while on LMWH/VKA
Visits in first 3 months 9 5 15 Gamma EINSTEIN DVT [25,51]
SIGN guidelines [15,51]
Visits each 3 months thereafter 5 2.5 10 Gamma BNF [18,51]
Recurrent VTE: proportion treated as outpatients rather than inpatients
Recurrent DVT patients (%) 69 50 100 Beta SIGN guidelines [15]
Incident PE patients (%) 17 0 30 Beta Survey data
Other
Proportion of patients requiring NHS-funded
transportation (%)
8.55 6 11 Beta Survey data
Proportion of CTEPH patients who require PEA (%) 68.40 64.20 72.60 Beta 321 of 469 patients from Condliffe
2008 [43]
Length of admission post DVT, days van Bellen 2014 [52]
LMWH/VKA 8* 4 10
Rivaroxaban 5* 3 9
Length of admission post PE, days van Bellen 2014 [52]
LMWH/VKA 7* 5 10
Rivaroxaban 6* 4 9
*Median values.
BNF, British National Formulary; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; INR, international normalized ratio; LMWH,
low molecular weight heparin; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; PE, pulmonary embolism; PEA, pulmonary
endarterectomy; SIGN, Scottish Intercollegiate Guidelines Network; VKA, vitamin K antagonist; VTE, venous thromboembolism.
Bamber et al. Thrombosis Journal  (2015) 13:20 Page 8 of 12duration groups. Rivaroxaban was also cost-effective in
the scenario analysis of patients requiring lifelong anticoa-
gulation, with ICERs of £8677 per QALY and £7072 per
QALY in patients with index DVT and PE, respectively.
Sensitivity analyses
Overall, more than 150 sensitivity analyses were con-
ducted for each of the patient groups evaluated. The
cost-effectiveness of rivaroxaban versus LMWH/VKA
was largely insensitive to variation in the assumptions
made. Notably, findings were stable when either savings
associated with earlier discharge in rivaroxaban patients
or warfarin disutility was removed. Sensitivity was great-
est to treatment effects and the frequency and cost of
INR monitoring, and an illustrative tornado plot for the
15 most sensitive parameters in the 6-month treatmentduration for DVT is provided in Figure 2 (Please see
Additional file 1: Figure S1 and Additional file 2: Figure
S2 for the complete set of parameters for 3, 6, 12 and
lifelong treatment duration for DVT and PE). Results
are shown using the Net Monetary Benefit measure at a
willingness to pay of £20,000 per QALY because pre-
senting ICER results was less meaningful owing to the
dominance of rivaroxaban.
The probabilistic sensitivity analyses demonstrated that
at a threshold of £20,000 per QALY, the probability of riv-
aroxaban being cost-effective in comparison with LMWH/
VKA was greater than 81%, regardless of index VTE or
whether a patient required 3, 6 or 12 months of anticoagu-
lation therapy. For patients requiring lifelong anticoagula-
tion, the likelihood was 80% and 78%, for DVT and PE
patients, respectively.
Figure 2 Tornado diagram of net monetary benefit of rivaroxaban versus LMWH/VKA. Patients requiring 6 months of anticoagulation. DVT, deep
vein thrombosis; GP, general practitioner; HR, hazard ratio; LMWH, low molecular weight heparin; OP, outpatient; OWSA, one-way sensitivity
analysis; PE, pulmonary embolism; QALY, quality-adjusted life-year; VKA, vitamin K antagonist; VTE, venous thromboembolism.
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The current analyses evaluated the cost-effectiveness of
rivaroxaban relative to dual LMWH/VKA therapy for
the treatment of VTE and associated complications. For
patients requiring up to 12 months of anticoagulant treat-
ment, rivaroxaban was associated with lower costs and
greater QALYs than dual LMWH/VKA therapy and,
therefore, dominated the current standard of care (dual-
drug therapy with LMWH/VKA) in the base case. For
patients requiring lifelong anticoagulation, rivaroxaban
had an ICER of below £9000 per QALY gained; therefore,
rivaroxaban can be considered cost-effective according to
commonly accepted UK willingness-to-pay thresholds.
Sensitivity analysis established that these findings were ro-
bust to input variation.
Several factors were identified as drivers of results.
Cost-effectiveness was found to be driven by improved
safety, in terms of fewer major bleeding events, leading
to a higher number of QALYs gained. Greater cost savings
and increased incremental QALYs for rivaroxaban were
associated with groups of patients requiring shorter dura-
tions of therapy and for whom earlier discharge is feasible.
A potential drawback of rivaroxaban, as with the other
novel anticoagulants, is the lack of a specific antidote. The
impact of this limitation on the cost-effectiveness model
would be mediated through either increased cost of bleed-
ing management or poorer patient outcomes in comparison
with VKAs, for which a slow acting antidote exists. How-
ever, evidence from the pooled EINSTEIN programme
data on the clinical impact of bleeding suggested that
major bleeding in the rivaroxaban arm had a milder clin-
ical presentation, and took a milder course, than LMWH/
VKA treatment [59]. Based on this evidence, no differentialassumptions on event costs or clinical outcomes after a
bleeding event have been applied. The availability of a spe-
cific reversal agent could potentially improve the existing
safety profile of rivaroxaban [60], providing a welcome
additional treatment option in case of life-threatening
bleeding, and further clinical reassurance. However, the
impact on overall cost-effectiveness would be limited.
Strengths and limitations
As with any economic evaluation, the current analyses
encompassed a number of strengths and limitations. An
area of weakness of the model is that there is no single
source for the resource use estimates, including fre-
quency of monitoring visits, proportion of patients who
require nursing assistance with injection and cost of
transportation to the healthcare facility for anticoagula-
tion monitoring. These assumptions were taken from
the results of literature searches and represent the best
available sources. However, the impact of rivaroxaban
will vary with local conditions, and this should be consid-
ered in the interpretation of the results. A particularly crit-
ical area of uncertainty identified a priori during model
development was INR monitoring frequency. Owing to
wide variation in both UK clinical practice and published
estimates [15,16,18,56], a service evaluation and national
survey were conducted to obtain the models of anticoagu-
lation, quantify its distribution and collect resource-use
data to ensure that the analysis represented clinical prac-
tice [51]. Local care pathways will determine whether such
savings can be realized consistently. However, several UK
institutions, including some London hospitals and the
Bradford and Sheffield NHS trusts, have already incorpo-
rated rivaroxaban into their standard VTE treatment
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cussions at formulary committee meetings and to inform
the structure of VTE care at the local level.
Inclusion of a disutility value for warfarin has further
been applied in the model base case to account for pa-
tient preference. Although, the evidence is not strong, it
is consistent, in that the significant patient burden asso-
ciated with the use of warfarin and monitoring has been
widely acknowledged. There is a degree of controversy
over whether this quality of life disutility is ‘health-
related’ and, therefore, should be appropriately consid-
ered from a health service perspective. We have taken
the view that patient preference should be considered in
the model base case, not least because there are aspects
driving patient preference, that impact on health-related
quality of life, including anxiety and uncertainty associ-
ated with staying in INR range. In addition, monitoring
may have limitations for patients through the requirement
for regular clinic attendance. Satisfaction with anticoagu-
lation was found to be higher with rivaroxaban compared
with LMWH/VKA in both the EINSTEIN DVT and
EINSTEIN PE trials, as measured using the Anti-Clot
Treatment Satisfaction (ACTS) scale. The ACTS ques-
tionnaire captures the patient perspective of burdens and
benefits of anticoagulation, including health-related qual-
ity of life elements, such as confidence, reassurance and
impact of bleeding and bruising on daily activities [49,50].
A limitation of using clinical study data to extrapolate
to a real-life scenario is that the population and or
disease management schedules may not be representa-
tive of daily care. However, the open-label design of
EINSTEIN DVT and EINSTEIN PE, together with the
limited exclusion criteria, flexibility of treatment dur-
ation, and availability of INR monitoring outside trial
centres, allowed a broad and representative population
to participate in the trials with a comparator relevant for
the UK setting. As with any trial or cohort study, the cen-
tres involved in recruiting patients have expertise and
interest in VTE treatment, and thus might be expected to
provide a higher than usual standard of care (for instance,
in maintaining higher time in INR target range).
Since rivaroxaban received marketing authorization
for the treatment of VTE, three anticoagulants have
received approval, apixaban, dabigatran and edoxaban,
with all three demonstrating similar efficacy compared
with the standard of care. In the UK setting, the NICE
and the Scottish Medicines Consortium have accepted the
cost-effectiveness of dabigatran in comparison with VKA,
with apixaban being currently under assessment by both
bodies. Determining the relative cost-effectiveness in the
absence of direct head-to-head trials would depend on in-
direct comparisons of the trial results, which can only be
considered as hypothesis-generating owing to differences
in trial design (open-label versus double-blind), inclusion/exclusion criteria and the regional settings of the trials.
Even then, residual bias or confounding will remain;
therefore, indirect comparison has not been pursued. Fur-
thermore, any differences in real-life cost-effectiveness of
the novel oral anticoagulant regimens may critically de-
pend on performance in real-life. This may include the
ability of each novel regimen to displace initial LMWH
therapy, supporting further out-of-hospital treatment,
as well as patient acceptance and persistence on ther-
apy, all of which are best assessed in real-life observa-
tional studies.
A scenario regarding treatment durations beyond those
examined in EINSTEIN DVT or EINSTEIN PE was in-
cluded in the analyses. This required assumptions regarding
the long-term effectiveness of rivaroxaban. Furthermore,
only limited trial data were available on the risk of VTE
among patients treated with VKA for beyond 12 months.
The data used in the model for the lifelong treatment sce-
nario were drawn from a meta-analysis of three clinical
trials [61]. However, the heterogeneity among these stud-
ies is acknowledged and highlights the continuing need
for further evidence regarding the benefit–risk assessment
of patients requiring long-term anticoagulation.
A main strength of this economic evaluation lies in
the comprehensive model structure fed by robust clinical
trials and extensive research to populate it. The model
was developed over the course of the EINSTEIN studies
in consultation with UK clinical and health economic ex-
perts, ensuring that the model clinical pathway was in line
with UK clinical practice. Furthermore, sensitivity analyses
have demonstrated the robustness of the findings.
These economic evaluations explored the long-term
health and cost benefits of rivaroxaban compared with
standard care in the treatment of patients with VTE
based on the findings of EINSTEIN DVT and EINSTEIN
PE [25,26]. Data from these studies provide further sup-
port for a shift in care in the treatment of VTE, which
may no longer call for initial parenteral anticoagulation
in some patients with DVT or PE.
Conclusion
Based on data from the EINSTEIN studies and known
local care pathways, this analysis suggests that rivaroxaban
represents a cost-effective choice for acute treatment of
DVT and PE and secondary prevention of VTE in the UK,
compared with LMWH/VKA treatment, regardless of the
required treatment duration.
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Additional file 1: Figure S1. Tornado diagram of net monetary benefit
of rivaroxaban versus LMWH/VKA for the treatment of DVT. Patients
requiring 3 months (a), 6 months (b), 12 months (c) and lifelong
anticoagulation (d). DVT, deep vein thrombosis; GP, general practitioner;
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